Oncology Central

Should busulfan now be part of the standard treatment for patients with acute myeloid leukemia?


Treatment of acute myeloid leukemia (AML) in nonelderly patients has followed the same paradigm of remission induction with cytarabine and anthracycline with or without a third cytotoxic drug for more than 40 years. These drugs produce complete remissions in the majority of patients, but cure requires intensive postremission treatment. Postremission therapies have also remained similar for many years, but better criteria for selection of postremission treatment for individual patients has improved results.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.